

5912
9/13/02
col

Patent
Attorney's Docket No. 032915-005

RECEIVED
MAY 28 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Roger LORIA


Application No.: 09/255,499

Filed: January 6, 1999

For: 5-ANDROSTENE-3 β , 17 α -DIOL AS AN
INHIBITOR OF TUMOR GROWTH

Group Art Unit: 1614

Examiner: J. Goldberg



**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of \$240.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e), a petition requesting consideration of the information disclosure statement, and the petition fee of \$130.00 (122) as set forth in 37 C.F.R. § 1.17(i) are also enclosed.
- Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \$ 140.00 is enclosed for the fee due.

The PTO did not receive the following
listed item(s). A check for \$ 240.00
but we got a check for \$ 140.00

Information Disclosure Statement Transmittal Letter
Application No. 09/255,499
Attorney's Docket No. 032915-005
Page 2

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Malcolm K. McGowan, Ph.D.
Registration No. 39,300

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: August 28, 2000